Accessibility Menu
SOPHiA GENETICS logo

SOPHiA GENETICS(NASDAQ) SOPH

Market Cap$682.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-51%
5 Year-57%
1 Year+146%
1 Month+47%
Premium Feature
Moneyball Superscore
71/100
$8.21
-7.96%
-0.71Today
Pre market$8.10-$0.11 (-1.34%)
SOPHiA GENETICS last closing stock price
MetricPriceDate
Last closeUSD 8.142026-08-28
SOPHiA GENETICS stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.9%USD 8.652026-08-21
1 month+46.67%USD 5.552026-07-29
3 month+61.19%USD 5.052026-05-29
Year to date+74.3%USD 4.672025-12-31
1 year+145.92%USD 3.312025-08-28
3 year+232.24%USD 2.452023-08-29
5 year-57.16%USD 19.002021-08-27
Since inception-51.43%USD 16.762021-07-23

SOPHiA GENETICS Financials at a Glance

Market Cap

$682.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$86.17M

Net Income (TTM)

-$80.88M

EPS (TTM)

-$1.15

P/E Ratio

-7.07

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$8.21

Volume

716.297

Open

$8.80

Previous Close

$8.14

Daily Range

$8.06 - $8.91

52-Week Range

$3.10 - $8.98

Estimated Earnings Date

Nov 3, 2026

SOPH News

No articles available.

SOPH: Motley Fool Moneyball Superscore

71

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SOPHiA GENETICS

SOPHiA GENETICS S.A. is a pioneering company in the healthcare technology sector, specializing in data-driven medicine. The firm offers the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution that analyzes diverse datasets to extract valuable insights for hospitals, laboratories, and biopharmaceutical organizations worldwide.

Products and Services
  • SOPHiA DDM platform for data analysis
  • Comprehensive analytics services for healthcare providers
  • Support for biopharmaceutical organizations in diagnostics
Growth Outlook
  • Revenue increased to $23.31 million in Q2 2026
  • Gross profit margin improved to 64.6% in Q2 2026
  • Cash and cash equivalents reached $107.67 million in Q2 2026
Financial Highlights
  • Trailing twelve months (TTM) revenue of $88.88 million
  • Operating income margin at -86% in Q2 2026
  • Current ratio of 2.69 indicates strong liquidity position
SOPHiA GENETICS S.A. has established itself as a leader in the healthcare technology space, leveraging advanced analytics to enhance diagnostic capabilities. The SOPHiA DDM platform is designed to integrate various data types, making it a valuable tool for healthcare professionals. The company's recent financial performance shows a notable increase in revenue, reflecting growing adoption of its services. The improvement in gross profit margin indicates effective cost management and operational efficiency. Furthermore, a robust cash position provides the company with the flexibility to invest in future growth initiatives. Overall, SOPHiA GENETICS S.A. presents a compelling opportunity within the healthcare technology sector, driven by innovation and a commitment to improving patient outcomes.
AI Generated • Aug 23, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

415

CEO

Jurgi Camblong, PhD, EMBA

Website

www.sophiagenetics.com

Headquarters

Rolle, VD 1180, CH

SOPH Financials

Key Financial Metrics (TTM)

Gross Margin

66.63%

Operating Margin

-85.01%

Net Income Margin

-93.86%

Return on Equity

-136.71%

Return on Capital

-64.38%

Return on Assets

-40.77%

Earnings Yield

-14.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$682.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

83.90M

Volume

716.297

Avg. Volume

384.19K

Financials (TTM)

Gross Profit

$57.41M

Operating Income

-$73.25M

EBITDA

-$65.11M

Operating Cash Flow

-$41.60M

Capital Expenditure

-$4.03M

Free Cash Flow

-$45.63M

Cash & ST Invst.

$107.67M

Total Debt

$61.83M

SOPHiA GENETICS Performance Analysis

SOPHiA GENETICS annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 47,560,00017.6%
20232023-12-31USD 62,371,00031.1%
20242024-12-31USD 65,173,0004.5%
20252025-12-31USD 77,271,00018.6%
SOPHiA GENETICS sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.2%
Q42025-12-3111.5%
Q12026-03-31-0.1%
Q22026-06-307.5%
SOPHiA GENETICS annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3618.3%
20232023-12-31USD -1.22-10.6%
20242024-12-31USD -0.95-22.4%
20252025-12-31USD -1.1723.6%
SOPHiA GENETICS sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.1%
Q42025-12-316.7%
Q12026-03-313.6%
Q22026-06-30-11.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$23.31M

+27.2%

Gross Profit

$15.06M

+22.7%

Gross Margin

64.61%

N/A

Market Cap

$682.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.65M

N/A

Employees

415

N/A

Net Income

-$22.36M

+0.3%

EBITDA

-$17.75M

+5.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$107.67M

+13.5%

Total Debt

$61.83M

-3.1%

Accounts Receivable

$14.11M

+48.5%

Inventory

$7.08M

+13.9%

Long Term Debt

$59.11M

-3.6%

Short Term Debt

$2.72M

+9.5%

Return on Assets

-40.77%

N/A

Return on Invested Capital

-49.73%

N/A

Free Cash Flow

-$10.39M

-2.0%

Operating Cash Flow

-$7.69M

+6.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRCNRC Health
$21.85-0.73%
LRMRLarimar Therapeutics, Inc.
$4.01-0.99%
SLPSimulations Plus, Inc.
$18.39-0.16%
CLLSCellectis S.A.
$3.40-3.14%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$49.82+0.10%
PCGPG&E
$16.60-0.08%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$111.34-0.10%
IBITiShares Bitcoin Trust
$43.90-0.03%

Questions About SOPH

What is the current price of SOPHiA GENETICS?

SOPHiA GENETICS is trading at $8.14 per share.

What is the 52-week range for SOPHiA GENETICS?

Over the past 52 weeks, SOPHiA GENETICS has traded between $3.10 and $8.98.

How much debt does SOPHiA GENETICS have?

As of the most recent reporting period, SOPHiA GENETICS reported total debt of $61.83M.

How much cash does SOPHiA GENETICS have on hand?

SOPHiA GENETICS reported $107.67M in cash and cash equivalents in its most recent financial results.

What is SOPHiA GENETICS’s dividend yield?

SOPHiA GENETICS does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services